Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study

Journal of Autoimmunity
Oscar Moreno-PérezEsperanza Merino

Abstract

To describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia. Case series of all sequential patients with severe COVID-19 pneumonia treated with TCZ at an Academic Spanish hospital (March 12 - May 2, 2020). Clinical outcomes: death, length of hospital stay. An early clinical response to TCZ (48-72 h after the administration) was assessed by variations in respiratory function markers, Brescia COVID Respiratory Severity Scale (BCRSS), inflammatory parameters, and patients' and physicians' opinion. Associations were tested by multiple logistic regression. From a cohort of 236 patients, 77 patients treated with TCZ were included (median age 62 years (IQR 53.0-72.0), 64.9% were males), 42.9% had Charlson index ≥3; hypertension (41.6%), obesity (34.7%), and diabetes (20.8%). Median follow-up was 83.0 days (78.0-86.5), no patient was readmitted. ICU admission was required for 42 (54.5%), invasive mechanical ventilation in 38 (49.4%) and 10 patients died (12.9% global, 23.8% at ICU admitted). After multivariate adjustment, TCZ response by BCRSS (OR 0.03 (0.01-0.68), p = 0.028), and Charlson index (OR 3.54 (1.20-10.44), p = 0.022) has been identified a...Continue Reading

Citations

Nov 17, 2020·Genome Génome / Conseil National De Recherches Canada·Wenxia LuoTed M Lakowski
Oct 30, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Miguel Górgolas Hernández-MoraGermán Peces-Barba Romero
Jan 22, 2021·BMJ : British Medical Journal·Viviane C VeigaUNKNOWN Coalition covid-19 Brazil VI Investigators
Jan 7, 2021·Infection and Drug Resistance·Abdullahi Rabiu AbubakarMainul Haque
Oct 30, 2020·International Journal of Molecular Sciences·Jan BrábekKarel Smetana
Sep 21, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Oscar Moreno-PUNKNOWN COVID19-ALC Research Group
Feb 28, 2021·Medicina clínica·Violeta Esteban RondaEsperanza Merino de Lucas
Mar 26, 2021·F1000Research·Cahyo Wibisono NugrohoJonny Karunia Fajar
Apr 2, 2021·Frontiers in Pharmacology·Zeinab AbdelrahmanXiaosheng Wang
Apr 11, 2021·Expert Review of Medical Devices·Maria Tsikala VafeaEleftherios Mylonakis
Jul 7, 2021·Medicina Clínica·Violeta Esteban RondaEsperanza Merino de Lucas
Jul 7, 2021·International Journal of Clinical Practice·Jose-Manuel Ramos-RinconUNKNOWN COVID-19 ALC Research Group
Aug 27, 2021·Therapeutic Advances in Chronic Disease·Jin-Tao GuanZheng-Hao Xu

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

BCRSS

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Related Papers

European Journal of Hospital Pharmacy. Science and Practice
Laetitia AlbertiniDany Goldgran-Toledano
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Manuel Rubio-RivasX. Corbella
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
T KlopfensteinHNF Hospital Tocilizumab multidisciplinary team
© 2021 Meta ULC. All rights reserved